@RheumNow video from #ACR22 Opioid use in PsA and SpA patients Discussing abstract 1012 by @AlexisOgdie https://t.co/fKRog1aIkH

Ab1012 #ACR22 @AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS 21% PsA pts on opioids, 27% AS on opioids Opioid users - more co-morbidities, 🚬, worse disease Tended to higher use of anti-rheumatic drugs Higher health care utilizations, medical $$ @RheumNow

CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc

• Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Art…

To propose early intervention in pre-clinical PsA we need to first identify pts! Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool Dvlped 600+ Pso M stiff, PASI, nails, fatigue pain severity Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui

Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H

• Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Populat…

Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69

• How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

Promising results for Izokibep in PsA Ph2 RCT meets primary endpoint at Wk 16 ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO MDA: 5% PBO 42% 40mg 39% 80mg Results observed as soon as wk2 No new safety signal compared to IL17Ai https://t.co/Gilhg5k36b Abs#1597 #ACR22 @RheumNow https://t.co/VvxSRLtkFk

• Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy …

Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539

• Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Paramete…

Baker et al, Corevitas registry in 7000+ RA pts Pts w/ moderate pain HR 1.37 Pts w/ severe pain HR 1.42 more likely to switch to diff MOA b/tsDMARD Adjusted for confounders incl DA Time we address pain separately to spare MAOs in a lifelong disease! Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m

Metabolic disorders +diet patterns PsA 👉71.9% obese 👉metabolic synd 46.9% 👉dyslipid 41.9% 👉 HTN 37.5% Diet patterns assoc Dx activity ⬇️sugar⬇️fatigue⬇️PSAID score ⬆️whole fruit ⬇️SJC ⬆️unsat fats ⬆️enthesitis DIPSA -Med/DASH diet PsA ongoing #ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp

#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO